In light of the recent sleep apnea discussion, I noticed this in a new article about the beneficial effects of Ozempic/Semaglutide on kidney patients.
Still, the results are the latest data to show that semaglutide can do more than treat diabetes or drive weight loss. In March, the F.D.A. authorized Wegovy for reducing the risk of cardiovascular issues in some patients. And scientists are examining semaglutide and tirzepatide, the compound in the rival drugs Mounjaro and Zepbound, for a range of other conditions, including sleep apnea and liver disease.
More details in the Working out / health and fitness thread